Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016) Sundar Jagannath, Rafat Abonour, Brian.

Slides:

Advertisements

Similar presentations

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Advertisements

Relapsed and Refractory Myeloma Case 2

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 88:226–235, R4 신재령.

Relapsed / Refractory Multiple Myeloma

Myeloma hope new treatment in the horizon

MRA Clinical Trials Day Myeloma UK Clinical Trial Network

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Andrzej Jakubowiak Seminars in Hematology

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Pieter Sonneveld,

Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma.

Future Strategies for Myeloma

Clinical Lymphoma, Myeloma and Leukemia

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Challenging Cases in Multiple Myeloma Panel Discussion

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis Meletios Athanasios.

Multiple Myeloma: Diagnosis and Treatment

Current Therapy for Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Multiple Myeloma:2013 Update Genomies

Therapy for Relapsed Multiple Myeloma

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data Kathleen Lang,

The Nurse View: Best Practices in Multiple Myeloma

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic.

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics Vincent T. Ma, Philip S. Boonstra,

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care.

Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma.

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,

New Classes of Therapy in Multiple Myeloma

Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries Roberto José Pessoa.

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world.

Relapsed/Refractory Myeloma: Foundational Knowledge Essential to Improve Patient Outcomes.

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

Genetic Mutations in B-Acute Lymphoblastic Leukemia Among African American and European American Children Amit Reddy, Ingrid Espinoza, Dana Cole, Jason.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature

Therapy for Relapsed Multiple Myeloma

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

On the Cusp: New Approaches for Multiple Myeloma

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV- associated Non-Hodgkin's Lymphoma (AMC-075) Juan C. Ramos, Joseph A. Sparano,

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab- Treated Patients With Relapsed or Refractory Multiple Myeloma Ajai Chari,

Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera.

Alex F. Herrera, Arturo Molina Clinical Lymphoma, Myeloma and Leukemia

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile):

Diagnosis of Multiple Myeloma

Renal Function and Myeloma Therapeutics

Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort.

Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice Abdalla Awidi, Salah Abbasi,

Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review Jill A. Bell, Aaron.

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Treatment options for relapsed and refractory multiple myeloma

Autologous Stem Cell Transplantation for POEMS Syndrome

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016) Sundar Jagannath, Rafat Abonour, Brian G.M. Durie, Cristina Gasparetto, James W. Hardin, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E.Dawn Flick, Amit Agarwal, Robert M. Rifkin Clinical Lymphoma, Myeloma and Leukemia Volume 18, Issue 7, Pages 480-485.e3 (July 2018) DOI: 10.1016/j.clml.2018.04.007 Copyright © 2018 The Authors Terms and Conditions

Figure 1 Second-Line Treatment Patterns, 2010-2016, Connect MM Registry. (A) Most Common Second-Line Treatments in 855 Patients. Gray Area at Right is Further Broken Down in (B). (B) Other Second-Line Treatments. Numbers Along y-axis are Total Number of Patients Initiating Therapy at Each Biannual Period Abbreviations: Be = bendamustine; Bor = bortezomib; C = carboplatin; Ci = cisplatin; Cy = cyclophosphamide; D = dexamethasone; Da = daratumumab; Do = doxorubicin; E = etoposide; El = elotuzumab; Fy = panobinostat; Ix = ixazomib; K = carfilzomib; Mel = melphalan; On = vincristine; Pe = pembrolizumab; Pom = pomalidomide; Pr = prednisone; R = lenalidomide; So = methylprednisolone sodium succinate; Th = thalidomide; Tx = paclitaxel; V = bortezomib. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 480-485.e3DOI: (10.1016/j.clml.2018.04.007) Copyright © 2018 The Authors Terms and Conditions

Figure 2 Second-Line Treatment Patterns by Agent and Patient Criteria. (A) Number of Agents (Single/Combination Regimens). (B) Agent Class. (C) Patient Age < 70 Years. (D) Patient Age ≥ 70 Years. Triplet and Quadruplet Regimens Include Patients Who Received Combinations of Chemotherapeutic Agents. Numbers Along y-axis are Total Number of Patients Initiating Therapy at Each Biannual Period Abbreviations: IMiD = immunomodulatory agent; mAb = monoclonal antibody; PI = proteasome inhibitor. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 480-485.e3DOI: (10.1016/j.clml.2018.04.007) Copyright © 2018 The Authors Terms and Conditions